17 completed, 6 terminated, 3 recruiting, 3 unknown. 34 Phase 3, 10 Phase 2.
Follow PTSD: new trials by email Literature Review of PTSD trials Research Report on PTSD
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Rapid Acceleration Process for Intensive Treatment of PTSD in 5 Days Transcranial magnetic stimulation, Sham transcranial magnetic stimulation - PTSD | Phase 3 | Not yet recruiting | VA Office of Research and Development | 90 | 2026-11-16 | 2026-10-05 |
| Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder COMP360 psilocybin - PTSD - Post Traumatic Stress Disorder, PTSD | Phase 2 / Phase 3 | Recruiting | COMPASS Pathways | 300 | 2026-09-01 | 2026-10-23 |
| Stellate Ganglion Block in the Treatment of Posttraumatic Stress Disorder 5 mL of 0.5% preservative-free bupivacaine - PTSD | Phase 3 | Enrolling by invitation | The Royal's Institute of Mental Health Research | 54 | 2024-03-30 | 2025-07-25 |
| Glecaprevir/Pibrentasvir for Post-traumatic Stress Disorder Glecaprevir/pibrentasvir, Placebo - PTSD | Phase 2 / Phase 3 | Unknown | White River Junction Veterans Affairs Medical Center | 92 | 2023-12-18 | 2025-04-24 |
| MDMA-assisted Brief Cognitive Behavioral Conjoint Therapy for PTSD 3,4-methylenedioxymethamphetamine (MDMA), Brief Cognitive Behavioral Conjoint Therapy (bCBCT) - PTSD, Relational Problems | Phase 3 | Completed | Dr. Leslie Morland | 16 | 2023-10-06 | 2025-12-08 |
| Repurposing Low-Dose Clonidine for PTSD in Veterans Clonidine Pill, Placebo - PTSD, Posttraumatic Stress Disorder | Phase 3 | Recruiting | Wake Forest University Health Sciences | 32 | 2023-06-01 | 2026-03-31 |
| Glecaprevir/Pibrentasvir for the Treatment of PTSD Glecaprevir / Pibrentasvir Pill - PTSD | Phase 2 / Phase 3 | Completed | White River Junction Veterans Affairs Medical Center | 10 | 2023-04-01 | 2024-08-29 |
| Treatment of Pediatric Post-traumatic Stress Disorder With Memory Reactivation Under the Influence of Propranolol Propranolol Oral Product, Placebo, memory reactivation - PTSD | Phase 3 | Recruiting | University Hospital, Toulouse | 92 | 2023-02-01 | 2023-08-28 |
| Safety and Efficacy of 50 mg NYX-783 QD vs. Placebo in PTSD NYX-783, Placebo - PTSD | Phase 2 / Phase 3 | Terminated | Aptinyx | 121 | 2021-12-13 | 2023-04-07 |
| Transcendental Meditation and PTSD TM, PCT - Ptsd, Depressive Symptoms | Phase 3 | Unknown | David Lynch Foundation | 450 | 2021-10-01 | 2021-04-22 |
| Psycho-educational Tool to Prevent Psychological Sequelae Following Paediatric Intensive Care Unit Admission Age-specific information booklet and targeted telephone call - PTSD | Phase 2 / Phase 3 | Unknown | Imperial College Healthcare NHS Trust | 288 | 2021-07-01 | 2022-03-24 |
| A Multi-Site Open-Label Extension Study of MDMA-Assisted Psychotherapy for PTSD Midomafetamine HCl - PTSD | Phase 3 | Completed | Resilient Pharmaceuticals | 87 | 2021-03-08 | 2025-06-06 |
| Estrogen and Fear in PTSD Estradiol, Placebo oral tablet, Prolonged Exposure (PE) therapy - PTSD | Phase 3 | Completed | The University of Texas Health Science Center, Houston | 83 | 2020-06-24 | 2026-01-09 |
| A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD TNX-102 SL, Placebo SL Tablets - PTSD | Phase 3 | Terminated | Tonix Pharmaceuticals, Inc. | 192 | 2019-03-07 | 2025-02-06 |
| Combined Treatment of Prolonged Exposure and Pramipexole for Posttraumatic Stress Disorder and Depression PE/Pramipexole - PTSD, MDD | Phase 3 | Terminated | Research Foundation for Mental Hygiene, Inc. | 1 | 2019-02-19 | 2019-11-26 |
| Epigenetics and MDMA-Assisted Psychotherapy for PTSD MDMA, Psychotherapy - PTSD | Phase 3 | Completed | University of Southern California | 45 | 2018-11-20 | 2026-05-04 |
| A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD TNX-102 SL 5.6 mg - PTSD | Phase 3 | Completed | Tonix Pharmaceuticals, Inc. | 93 | 2018-04-19 | 2025-02-05 |
| Ketamine Infusion for Comorbid PTSD and Chronic Pain A single low dose ketamine infusion as compared to the IV infusion of active placebo - ketorolac on chronic pain and PTSD symptoms. - PTSD, Chronic Pain | Phase 3 | Completed | VA Ann Arbor Healthcare System | 41 | 2018-01-09 | 2020-12-22 |
| Pharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUD Pregabalin plus BBCET, Placebo plus BBCET - PTSD, Alcohol Use Disorder | Phase 3 | Completed | University of Maryland, Baltimore | 57 | 2017-07-07 | 2024-03-13 |
| 12-Week Open-Label Extension Study of TNX-102 SL in PTSD Patients TNX-102 SL - PTSD | Phase 3 | Terminated | Tonix Pharmaceuticals, Inc. | 190 | 2017-06-20 | 2025-02-06 |
Showing 20 of 34. Sign in to see all of them.
Stress Disorders, Post-Traumatic (34) · Alcoholism (4) · Depression (3) · Hepatitis C (2) · Alcohol Drinking (1) · Anxiety Disorders (1) · Chronic Pain (1) · Combat Disorders (1) · Pain (1) · Parasomnias (1) · Sleep Wake Disorders (1) · Suicidal Ideation (1) · Wounds and Injuries (1)
Mental Disorders (34) · Stress Disorders, Traumatic (34) · Trauma and Stressor Related Disorders (34) · Alcohol-Related Disorders (4) · Chemically-Induced Disorders (4) · Substance-Related Disorders (4) · Behavior (3) · Behavioral Symptoms (3) · Neurologic Manifestations (3) · Pathological Conditions, Signs and Symptoms (3) · Signs and Symptoms (3) · Blood-Borne Infections (2) · Communicable Diseases (2) · Digestive System Diseases (2) · Flaviviridae Infections (2)
N-Methyl-3,4-methylenedioxyamphetamine (2) · Paroxetine (2) · glecaprevir and pibrentasvir (2) · Clonidine (1) · Cycloserine (1) · Desipramine (1) · Estradiol (1) · Ketamine (1) · Midazolam (1) · Naltrexone (1) · Prazosin (1) · Pregabalin (1) · Propranolol (1) · Psychotherapy (1) · Therapeutics (1)
Tonix Pharmaceuticals, Inc. (4) · VA Office of Research and Development (4) · Yale University (3) · White River Junction Veterans Affairs Medical Center (2) · Adriana Feder (1) · Aptinyx (1) · Boston University Charles River Campus (1) · COMPASS Pathways (1) · David Lynch Foundation (1) · Dr. Leslie Morland (1) · H. Lundbeck A/S (1) · Imperial College Healthcare NHS Trust (1) · Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital (1) · Research Foundation for Mental Hygiene, Inc. (1) · Resilient Pharmaceuticals (1)
United States (27) · Canada (3) · France (2) · Denmark (1) · Estonia (1) · Finland (1) · Germany (1) · Israel (1) · Italy (1) · Poland (1) · Serbia (1) · South Africa (1) · Sweden (1) · United Kingdom (1)
Bradley V Watts, MD, MPH (2) · Ismene L Petrakis, MD (2) · Adriana Feder, MD (1) · Candice M Monson, PhD (1) · Denise Bedoya (1) · Greg Sullivan, MD (1) · Gregory Burek, MD, MS (1) · Gregory M Sullivan, MD (1) · Ismene Petrakis, M.D. (1) · Joseph K Carpenter, M.A. (1) · Julian D Ford, Ph.D. (1) · Leslie Morland (1) · Lori Lynne Davis, MD AB (1) · Maja Sticker Nordbrandt, MD (1)
PMID 18204347, PMID 22089316, PMID 26492879, PMID 29414272, PMID 32163509, PMID 33587394, PMID 34291990, PMID 36815187, PMID 38113919, PMID 38350291, PMID 38994348, PMID 40483726, PMID 41015488
R01AA024760 (1), R33MH111907 (1)